|
Collaborative and Other Research and Development Contracts - Additional Information (Detail) (USD $)
|
0 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nov. 17, 2011
|
May 31, 2010
|
Dec. 31, 2013
UAB [Member]
Agreement
|
Feb. 24, 2011
U.S. Department of Health and Human Services [Member]
|
Sep. 30, 2009
U.S. Department of Health and Human Services [Member]
|
Jan. 31, 2007
U.S. Department of Health and Human Services [Member]
|
Dec. 31, 2013
U.S. Department of Health and Human Services [Member]
|
Sep. 30, 2013
National Institute of Allergy and Infectious Diseases [Member]
|
Dec. 31, 2013
National Institute of Allergy and Infectious Diseases [Member]
|
Jun. 30, 2006
Green Cross Corporation [Member]
|
Feb. 28, 2006
Mundipharma International Holdings Limited [Member]
|
Dec. 31, 2012
Mundipharma International Holdings Limited [Member]
|
Nov. 11, 2011
Mundipharma International Holdings Limited [Member]
|
May 31, 2010
AECOM and IRL [Member]
|
Jun. 30, 2000
AECOM and IRL [Member]
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||||||
| Collaborative agreement contract value | $ 102,661,000 | ||||||||||||||
| Collaborative agreement period of agreement | 4 years | 5 years | |||||||||||||
| Collaborative agreement additional contract period | 12 months | ||||||||||||||
| Collaborative agreement additional contract value | 55,000,000 | 77,191,000 | |||||||||||||
| Collaborative agreement adjusted contract value | 234,852,000 | ||||||||||||||
| Collaborative agreement initial payment | 5,000,000 | ||||||||||||||
| Collaborative agreement contract value | 22,000,000 | ||||||||||||||
| Collaborative agreement exercised options awarded | 7,500,000 | ||||||||||||||
| License fee received | 250,000 | ||||||||||||||
| Up-front payment receivable amount | 10,000,000 | ||||||||||||||
| Deferred revenue up-front payment receivable | 10,000,000 | ||||||||||||||
| Deferred revenue initiation of clinical trial payment received | 5,000,000 | ||||||||||||||
| Potential milestone payments receivable | 15,000,000 | ||||||||||||||
| Unamortized deferred revenue, related to Amended and Restated Agreement | 7,766,000 | ||||||||||||||
| Unamortized deferred expenses, related to Amended and Restated Agreement | 1,864,000 | ||||||||||||||
| Milestone payment minimum | 1,400,000 | ||||||||||||||
| Milestone payment maximum | 4,000,000 | ||||||||||||||
| Annual license fees minimum | 150,000 | ||||||||||||||
| Annual license fees maximum | 500,000 | ||||||||||||||
| Advance notice period for termination of agreement | 60 days | ||||||||||||||
| Reduction in the percentage of future payments | 0.5 | ||||||||||||||
| Stock issued during period value for modification of license agreement | 5,911,000 | ||||||||||||||
| Payments for modification of license agreement | $ 90,000 | ||||||||||||||
| Royalty reduction percentage of net proceeds | 0.5 | ||||||||||||||
| Number of agreements | 2 | ||||||||||||||
| Period of agreement | 25 years | ||||||||||||||
| Renewable period of agreement | 5 years | ||||||||||||||